Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

ADIL

Adial Pharmaceuticals Inc

May 17 • 04:00PM ET

1.55

Dollar change +0.14
Percentage change 9.93	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.88	Insider Own	2.78%	Shs Outstand	4.23M	Perf Week	3.33%
Market Cap	6.56M	Forward P/E	-	EPS next Y	-1.59	Insider Trans	0.00%	Shs Float	4.12M	Perf Month	-28.57%
Income	-11.32M	PEG	-	EPS next Q	-1.26	Inst Own	3.68%	Short Float	4.05%	Perf Quarter	34.78%
Sales	0.00M	P/S	-	EPS this Y	35.83%	Inst Trans	-	Short Ratio	0.03	Perf Half Y	-26.92%
Book/sh	1.51	P/B	1.03	EPS next Y	30.95%	ROA	-212.33%	Short Interest	0.17M	Perf Year	-81.44%
Cash/sh	1.19	P/C	1.30	EPS next 5Y	-	ROE	-297.26%	52W Range	0.76 - 14.00	Perf YTD	-16.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	38.36%	ROI	-184.90%	52W High	-88.93%	Beta	1.28
Dividend TTM	-	Quick Ratio	9.48	Sales past 5Y	0.00%	Gross Margin	-	52W Low	102.61%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	9.48	EPS Y/Y TTM	52.60%	Oper. Margin	0.00%	RSI (14)	46.72	Volatility	10.67% 10.21%
Employees	7	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.67	Target Price	7.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	20.13%	Payout	-	Rel Volume	0.02	Prev Close	1.41
Sales Surprise	-	EPS Surprise	11.96%	Sales Q/Q	-	Earnings	Nov 14 BMO	Avg Volume	6.37M	Price	1.55
SMA20	-5.62%	SMA50	-9.04%	SMA200	-30.02%	Trades		Volume	135,158	Change	9.93%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-30-18	Initiated	Maxim Group	Buy	$5
Oct-11-18	Initiated	Dawson James	Buy

May-15-24 09:54AM	ADIL Stock Earnings: Adial Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace)
08:30AM	Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-22-24 10:00AM	EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent (Benzinga)
08:30AM	Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office (GlobeNewswire)
Apr-10-24 11:53AM	Why Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today? (InvestorPlace) +106.19%
08:30AM	Loading…
08:30AM	Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder (GlobeNewswire)
Apr-02-24 08:30AM	Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-24 07:00PM	Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds (GlobeNewswire) +59.80%
Feb-28-24 09:30AM	Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office (GlobeNewswire) +85.50%
Feb-15-24 09:00AM	Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20 (ACCESSWIRE)
Feb-13-24 09:15AM	Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office (GlobeNewswire) +8.72%
Jan-18-24 08:30AM	Adial Announces Appointment of Tony Goodman as Chief Operating Officer (GlobeNewswire)
Dec-20-23 09:00AM	Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate (GlobeNewswire)
Nov-29-23 04:05PM	Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement (GlobeNewswire)
Nov-14-23 05:02PM	Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.46%
08:30AM	Loading…
Oct-31-23 08:30AM	Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss New Aspects in Substance Use Treatment at The Annual International Society of Addiction Medicine Conference (GlobeNewswire)
Oct-30-23 12:00PM	All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy (Zacks)
Oct-25-23 08:00AM	Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar (GlobeNewswire)
Oct-24-23 04:30PM	Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Oct-20-23 08:00AM	Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.11%
Oct-19-23 12:00PM	EXCLUSIVE: Adial Pharma Announces Key Patent To Combine Genetic Diagnostic With Lead Drug For Alcohol Addiction (Benzinga)
12:00PM	Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th (ACCESSWIRE)
10:30AM	Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence (GlobeNewswire)
Oct-18-23 08:00AM	Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award (GlobeNewswire)
Sep-28-23 07:00AM	Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder (GlobeNewswire) -9.79%
Sep-05-23 08:30AM	Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-28-23 08:30AM	Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism (GlobeNewswire)
Aug-23-23 08:30AM	Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Aug-21-23 08:30AM	Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-23 08:30AM	Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaqs Minimum Bid Price Requirement and Reduce the Public Float (GlobeNewswire)
09:59AM	Loading…
Jul-19-23 09:59AM	Adial (ADIL) Shares Up 43% in the Past Week: Here's Why (Zacks)
Jul-11-23 08:30AM	Adial Provides Business Update Following Favorable Comments from US and EU Regulatory Meetings (GlobeNewswire) +90.31%
Jun-01-23 09:00AM	Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th (GlobeNewswire)
May-12-23 08:30AM	Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -5.49%
May-10-23 08:30AM	Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovates Assets and Business (GlobeNewswire)
Apr-04-23 09:40AM	Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-30-23 04:05PM	Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update (GlobeNewswire)
Mar-21-23 09:00AM	Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder (GlobeNewswire)
Mar-08-23 09:00AM	Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th (GlobeNewswire) +11.99%
Mar-07-23 01:51PM	Adial Pharma Sees Clear, Cost-Effective Path Toward FDA Approval For Alcohol Use Disorder Candidate (Benzinga) +5.45%
10:46AM	Metas stock up on report of more layoffs, and WeightWatchers telehealth deal gives it access to promising obesity drug market (MarketWatch)
08:05AM	Meta shares rise after new wave of layoffs, WeightWatchers stock makes gains after results and acquisition; Grindrs stock falls after profit drop (MarketWatch)
Mar-06-23 04:19PM	Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder (GlobeNewswire)
Mar-02-23 09:00AM	Adial Pharmaceuticals Schedules Business Update Conference Call (GlobeNewswire)
Feb-28-23 05:27AM	Adial Pharmaceuticals, Inc. (NASDAQ:ADIL): Is Breakeven Near? (Simply Wall St.)
Feb-27-23 09:00AM	Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering (GlobeNewswire) -9.98%
Feb-24-23 07:00AM	Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering (GlobeNewswire)
Feb-21-23 09:00AM	Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder (GlobeNewswire)
Feb-01-23 09:00AM	Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed (GlobeNewswire)
Dec-01-22 09:55AM	Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-14-22 08:30AM	Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-19-22 04:57PM	Forget Bargain Hunting: Play 5 Stocks With Rising P/E (Zacks) -6.10%
Sep-26-22 12:43PM	Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate (Benzinga)
09:00AM	Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovates PNV-5030 as a Potential Treatment for Chronic Pain (GlobeNewswire)
Sep-06-22 10:02AM	Adial Pharma's Subsidiary Shows Encouraging Preclinical Action For Inflammatory Bowel Disease Candidate (Benzinga)
09:00AM	Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovates PNV-6005 as a Potential Treatment for Ulcerative Colitis (GlobeNewswire)
Sep-01-22 09:55AM	Here's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom Fisher (Zacks)
Aug-29-22 07:19AM	Zacks.com featured highlights include Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight Enterprises (Zacks)
Aug-26-22 07:42AM	Forget Bargain Hunting: Play 5 Stocks With Rising P/E (Zacks)
Aug-22-22 04:30PM	Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer (GlobeNewswire) -5.93%
Aug-16-22 09:15AM	Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-20-22 07:00AM	Adial Pharmaceuticals Announces Topline Results For Onward Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder (GlobeNewswire) -46.74%
06:45AM	EXCLUSIVE: Adial Pharma's AD04 Effective In Heavy Drinker Alcohol Use Disorder Patients (Benzinga)
Jul-18-22 09:25AM	Adial Pharmaceuticals to Announce Topline Results of ONWARD Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder (GlobeNewswire) +10.43%
Jun-28-22 11:49AM	Adial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley (GlobeNewswire) -8.94%
Jun-27-22 09:16AM	Adial Pharmaceuticals Announces Database Lock for the ONWARD Phase 3 Clinical Trial (GlobeNewswire)
Jun-14-22 10:48AM	Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Companys Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence (GlobeNewswire) -7.58%
09:55AM	Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-19-22 09:25AM	Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovates Adenosine Compounds as Potential Treatments for Diabetes and NASH (GlobeNewswire)
May-16-22 09:25AM	Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire) +10.94%
May-05-22 04:05PM	Maravai LifeSciences Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-04-22 09:15AM	Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovates Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders (GlobeNewswire)
Apr-06-22 07:47AM	5 Winning Stocks Backed by the Overlooked Rising P/E Strategy (Zacks) -10.63%
Mar-22-22 09:15AM	Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th (GlobeNewswire)
Feb-24-22 09:15AM	Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder (GlobeNewswire) +9.00%
Feb-16-22 09:26AM	Adial Pharmaceuticals Announces Closing of $10 Million Financing (GlobeNewswire)
Feb-11-22 09:00AM	Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering (GlobeNewswire) -13.89%
Feb-09-22 09:25AM	Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovates PNV-5032 as a Potential Treatment for Asthma (GlobeNewswire)
Jan-24-22 09:25AM	Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04 (GlobeNewswire)
Jan-12-22 09:40AM	Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-10-22 09:03AM	Adial Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2022 Conference (GlobeNewswire)
Dec-22-21 09:25AM	Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share (GlobeNewswire)
Dec-08-21 09:25AM	Adial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Company as Chief Operating Officer (GlobeNewswire) +6.14%
Nov-29-21 09:00AM	Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer (GlobeNewswire) -10.18%
Nov-17-21 09:42AM	REMINDER: Adial Pharmaceuticals to Host Conference Call Thursday, November 18, 2021 at 11:00AM Eastern to Provide Clinical Update and Discuss Latest Developments (GlobeNewswire)
Nov-10-21 09:26AM	Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options (GlobeNewswire)
Nov-09-21 09:15AM	Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments (GlobeNewswire) +7.44%
Nov-03-21 09:10AM	Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors (GlobeNewswire)
Oct-21-21 01:06PM	Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate (Benzinga) -7.89%
10:13AM	Adial Announces Positive Pre-Clinical Data for Purnovates PNV-5030 as a Drug Candidate for the Treatment of Pain (GlobeNewswire)
09:45AM	Adial Announces Positive Pre-Clinical Data for Purnovates PNV-5030 as Drug Candidate for the Treatment of Pain (GlobeNewswire)
Oct-18-21 09:30AM	Adial Pharmaceuticals to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021 (GlobeNewswire)
Oct-05-21 09:25AM	Adial Pharmaceuticals to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Tuesday, October 5, 2021 (ACCESSWIRE)
Oct-04-21 04:30PM	36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021 (ACCESSWIRE) -9.83%
Sep-30-21 09:25AM	Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period Trial Completion Anticipated Q1 2022 (GlobeNewswire)
Sep-28-21 09:49AM	Adial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing (GlobeNewswire) -5.09%
Sep-15-21 10:07AM	Adial CEO William Stilley Invited to Participate in Maxim Groups Virtual Panel Series Conference: Disruptors in the Mental Health Space (GlobeNewswire)
Sep-13-21 09:30AM	Sysorex Elects Nasdaq-Listed Company CEO William Stilley to Board of Directors (GlobeNewswire)
Sep-07-21 09:00AM	Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-31-21 09:30AM	Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder (GlobeNewswire)

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schuyler Kevin	Director	Sep 29 '23	Buy	2.74	700	1,918	700	Oct 03 08:54 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADIL

Adial Pharmaceuticals Inc

Upgrade your FINVIZ experience